These innovative compounds represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://minarzcp380486.blogdomago.com/37764204/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide